(vianews) - sanofi (san.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| sanofi (san.pa) | €90.96 | 4.31% | 7.27% |
| ucb (ucb.br) | €114.05 | 1.19% | 3.8% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. sanofi (san.pa)
4.31% forward dividend yield and 7.27% return on equity
sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the united states, europe, and internationally. it operates through pharmaceuticals, vaccines, and consumer healthcare segments. the company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. in addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis a, typhoid, cholera, yellow fever, and rabies vaccines. the company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. further, it has a collaboration and license agreement with exscientia to develop up to 15 novel small-molecule for oncology and immunology; abl bio, inc. to develop abl301, a treatment for alpha-synucleinopathies; blackstone life sciences to develop pivotal studies and clinical development program; and seagen inc. to design, develop, and commercialize antibody-drug conjugates for cancer. additionally, the company has a collaboration agreement with igm biosciences, inc. to develop, manufacture, and commercialize igm antibody; skyhawk therapeutics, inc to discover and develop novel small molecules; and adagene inc., for the discovery and development of antibody-based therapies. it also has collaborations with scribe therapeutics inc. to develop genome editing technologies; and co-promotion service agreement with provention bio, inc. for the commercialization of teplizumab. the company was formerly known as sanofi-aventis and changed its name to sanofi in may 2011. sanofi was founded in 1973 and is headquartered in paris, france.
earnings per share
as for profitability, sanofi has a trailing twelve months eps of €4.3.
pe ratio
sanofi has a trailing twelve months price to earnings ratio of 21.15. meaning, the purchaser of the share is investing €21.15 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.27%.
yearly top and bottom value
sanofi's stock is valued at €90.96 at 07:30 est, way under its 52-week high of €105.18 and way above its 52-week low of €80.60.
volatility
sanofi's last week, last month's, and last quarter's current intraday variation average was a negative 0.44%, a negative 0.04%, and a positive 0.75%.
sanofi's highest amplitude of average volatility was 0.69% (last week), 0.73% (last month), and 0.75% (last quarter).
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, sanofi's stock is considered to be overbought (>=80).
dividend yield
as maintained by morningstar, inc., the next dividend payment is on may 13, 2024, the estimated forward annual dividend rate is 3.76 and the estimated forward annual dividend yield is 4.31%.
more news about sanofi.
2. ucb (ucb.br)
1.19% forward dividend yield and 3.8% return on equity
ucb sa, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. the company's primary products include cimzia for inflammatory tnf mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; vimpat, keppra, and briviact for epilepsy; neupro for parkinson's disease and restless legs syndrome; nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and zyrtec and xyzal for allergies. it also offers evenity for the treatment of osteoporosis in postmenopausal women; bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and fintepla to treat dravet syndrome. in addition, the company is involved in developing rozanolixizumab and zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat cdkl5 deficiency disorder; doxecitine for tk2 deficiency disorder; staccato alprazolam for stereotypical prolonged seizures; bepranemab to treat alzheimer's disease; minzasolmin and ucb0222 for parkinson's disease; and ucb1381 and ucb9741 for atropic dermatitis. further, it engages in contract manufacturing activities. ucb sa has collaboration agreements with amgen, biogen, roche/genentech, novartis, and otsuka. the company was incorporated in 1925 and is headquartered in brussels, belgium.
earnings per share
as for profitability, ucb has a trailing twelve months eps of €1.76.
pe ratio
ucb has a trailing twelve months price to earnings ratio of 64.8. meaning, the purchaser of the share is investing €64.8 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.8%.
sales growth
ucb's sales growth for the current quarter is 6.6%.
more news about ucb.